KNE — Kane Biotech Cashflow Statement
0.000.00%
Last trade - 00:00- CA$6.63m
- CA$7.62m
- CA$2.08m
Annual cashflow statement for Kane Biotech, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | C2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -3.85 | -4.85 | -3.82 | -5.27 | 6.17 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.097 | 0.722 | 0.123 | 1.23 | -8.87 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.268 | 1.65 | 0.394 | 1.72 | -0.32 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -3.94 | -2.29 | -3.04 | -2.08 | -4.11 |
| Capital Expenditures | -0.126 | -0.354 | -0.088 | -0.05 | -0.09 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -0.04 | -0.02 | -0.02 | 0.76 | 10.4 |
| Sale of Business | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.166 | -0.374 | -0.108 | 0.711 | 10.3 |
| Financing Cash Flow Items | 1.23 | 0.445 | -0.121 | 0.212 | -1.53 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 4.28 | 2.81 | 3.1 | 2.16 | -7.69 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.174 | 0.145 | -0.048 | 0.784 | -1.53 |